RxDoctor Payments Data

Lisa Ferreira, MD

Obesity Medicine · Wesley Chapel, FLNPI 1619928652

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $174,816 of the $182,595 with a category attached, or 95.7%. 11 manufacturers reported payments, led by Lilly USA, LLC at 59.3% of the total. 2025 is the largest year on record at $86,559, more than ten times the $92 reported in 2019. Among obesity medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$182,595in general payments, 2019–2025

Across 251 payments — averaging $727.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$108K
  • Novo Nordisk$73K
  • Medtronic$452
  • Intuitive Surgical$244
  • Linvatec Corporation$155
  • Conmed Corporation$125
  • plus $180 from 5 others

What the payments were for

  • Speaking & faculty fees$174,81696%
  • Travel & lodging$2,0891%
  • Food & beverage$5,6903%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$182,595 in reported general payments places this provider in the 95th percentile of 21 obesity medicine providers in Florida.

See all obesity medicine providers in Florida

Medicare billing

Part B allowed, 2024
$41,605
Medicare patients
75
Services billed
306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide244$267,612
MounjaroTirzepatide70$74,067
WegovySemaglutide32$44,558
Bupropion XlBupropion Hcl29$925
Metformin Hcl ErMetformin Hcl89$695
Topiramate62$502
Ondansetron OdtOndansetron19$277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$73,112$312,170276 claims
Lilly USA, LLCMounjaro$108,327$74,06770 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 obesity medicine providers in Florida.

Other obesity medicine in Wesley Chapel

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →